Cellectar Biosciences (CLRB) Q3 2026 earnings review
Cellectar opens Phase 3 trial sites, but cash burns fast
Cellectar Biosciences, a clinical-stage developer of targeted radioactive cancer drugs, spent faster to start its pivotal blood-cancer trial while its cash cushion shrank. Research and development costs more than doubled from a year ago as initial Phase 3 sites opened and a new FDA-requested dosing study began. Chief executive James Caruso kept the first-quarter 2027 target for dosing the first Phase 3 patient, and by our math the $9 million quarterly cash burn matched what the company's runway plan pointed to.
| Cash and cash equivalents | $24.6M $34.0M last quarter |
|---|---|
| Research and development expenses | $5.4M +115% from a year ago |
| Net loss | $8.0M $4.4M a year ago |
| Cash runway outlook | Unchanged funds operations into Q2 2027 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because clinical preparation is moving forward on schedule, but the funding gap in mid-2027 remains just as tight. Activating initial Phase 3 sites and placing a $2 million deposit with its trial manager show real progress toward a first-half 2027 regulatory filing. One caution: cash still runs out in the second quarter of 2027, right when that filing is due, and the breast-cancer readout scheduled for late 2026 quietly dropped efficacy data from its scope.
The question now is whether Cellectar can start its Phase 3 trial and file for US approval before needing another dilutive cash raise. Either early 2027 clinical milestones allow the company to collect $35 million from existing warrant holders, or it must raise fresh capital to bridge the gap to regulatory review. First-quarter 2027 patient dosing and warrant exercises will settle it.
🐂 Bull Case
Phase 3 Startup Advances With Initial Sites Open
Cellectar Biosciences develops targeted cancer drugs that deliver radioactive isotopes directly to tumor cells. To win accelerated approval for its lead drug, iopofosine I 131, in Waldenström macroglobulinemia (WM), a rare blood cancer, the US regulator requires an active Phase 3 trial at the time of filing.
During the third quarter, the drugmaker activated initial clinical sites and placed $2.3 million on deposit with its contracted research organization. Research and development spending more than doubled from a year ago to $5.4 million, or 67.1% of total operating expenses, because of this trial startup. That spending keeps the plan on track to dose the first patient in the first quarter of 2027.
What to watch: confirmation that the first Phase 3 patient receives a dose in the first quarter of 2027. Hitting that deadline unlocks the 2027 filing schedule and satisfies the clinical requirement for the first tranche of milestone warrants.
Targeted Radiotherapy Shows Strong Responses After BTKi Failure
Chief executive James Caruso said updated data from the Phase 2b trial strengthen confidence in iopofosine I 131 by "demonstrating high response rates, durable outcomes and a favorable safety profile in a difficult-to-treat post-BTK inhibitor patient population". Bruton Tyrosine Kinase inhibitors (BTKi) are standard pills for WM, and patients who relapse after taking them have few remaining options.
- Overall response rate: 87.5% across 24 evaluable patients treated right after BTKi failure
- Major response rate: 79.2%, compared with 61.8% in the broader Phase 2b trial
- Median duration of response: 16.0 months, with 19.1 months of treatment-free survival
- New Phase 1b dosimetry study: enrolling 20 to 30 patients across all treatment lines
This subset matches the exact patient group in the confirmatory Phase 3 trial. The biotechnology group also noted "significantly longer duration of response among patients treated after only two prior lines of therapy compared with more heavily pretreated patients", which supports testing the drug earlier in the disease.
What to watch: the detailed Phase 3 trial design and 12-month follow-up posters at the hematology meeting in December 2026. The data will show how much longer responses last in second-line patients compared with later lines.
🐻 Bear Case
Cash Runs Out Right Around the Planned FDA Filing
Cellectar plans "to submit in 1H27 a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking accelerated approval". At the same time, the company says its $24.6 million cash balance is "adequate to fund its budgeted operations into the second quarter of 2027".
Those two dates collide. By our math, cash fell by $9.4 million in the third quarter, and lasting into the second quarter of 2027 leaves an average burn of about $9.8 million per quarter. That means cash runs out right as the company files its application, before the regulator can accept the filing and trigger the second tranche of May 2026 milestone warrants.
Even the first $35 million warrant tranche, tied to dosing the first Phase 3 patient in early 2027, cannot be forced by the company unless its volume-weighted average share price meets a strict threshold for 20 trading days. Without that cash, the drugmaker will need another financing before mid-2027.
What to watch: year-end cash in the fourth-quarter report and any financing announcements before the first quarter of 2027 ends. A cash balance near $15 million at year-end without warrant exercises would leave less than two quarters of funding.
Dilution Multiplies Share Count Over Fivefold
On the income statement, third-quarter net loss per share shrank from $1.41 a year ago to $0.46. That drop did not come from lower spending; total net loss widened by 79.5% to $8.0 million as clinical trial costs ramped up.
Per-share loss fell only because repeated equity offerings multiplied the share count. Weighted-average basic and diluted shares rose 452.3% from a year ago to 17.5 million, and rose 42.8% just from the second quarter. Common shares issued on the balance sheet climbed 21.7% in the quarter to 10.0 million as holders converted pre-funded warrants from the May 2026 raise.
What to watch: weighted-average diluted share count in the fourth-quarter report. Further conversion of the remaining pre-funded warrants will continue expanding the issued share base before any milestone warrants are exercised.
Breast Cancer Data Narrowed After Missing Mid-Year Target
Outside of blood cancer, Cellectar is testing CLR 121125 (CLR 125), a radioactive iodine-125 drug for solid tumors, in a Phase 1b study for triple-negative breast cancer. In its fourth-quarter 2025 and first-quarter 2026 reports, the company planned to release early dosimetry, safety and efficacy data from this study by mid-year 2026.
Mid-year passed without data, and the third-quarter release states that only initial dosimetry and safety data are "expected to be shared in the fourth quarter of 2026 at a medical meeting". Dropping efficacy from the promised fourth-quarter readout means the solid-tumor platform will not show tumor-shrinkage proof this year.
What to watch: the Phase 1b CLR 125 presentation in the fourth quarter of 2026. The readout will show whether radiation reaches breast tumors safely and when the company expects to report actual tumor response rates.
Risks this quarter didn't answer
Four standing clinical, regulatory and commercial concerns received no resolution in the third-quarter release.
- European regulatory filing: previously planned for a third-quarter 2026 conditional marketing submission, the European Medicines Agency was not mentioned in the release; the quarterly filing will show if the timeline remains active.
- Blood-count side effects: the release noted the "only Grade 3 or higher TEAE being cytopenias" (low blood cell counts) in under 10% of the subset, whereas the full trial previously showed Grade 3+ low platelets in 81.5% of patients; December posters will clarify the exact hematologic rates.
- Commercial buildout: management previously estimated a 12-month buildout after approval and has not chosen between a partner and self-commercialization; partnership updates remain pending.
- Phase 3 enrollment duration: enrolling 200 patients across two arms takes 18 to 24 months from the first patient in early 2027, leaving full approval years away.
💲 Other KPIs
Cellectar recorded a new $2.28 million long-term deposit with its contracted research organization this quarter, up from zero at the end of 2025. This upfront payment for the Phase 3 WM trial accounted for 24.3% of the $9.41 million third-quarter cash decrease by our math, showing that cash burn jumped ahead of recorded expenses.
Overhead and administrative spending rose 14.6% from a year ago and 1.1% from the second quarter, driven by higher professional fees and personnel costs. That follows three straight quarters of year-over-year declines after the late-2024 restructuring cut commercial staff, leaving overhead at 32.9% of total operating expenses.
Unpaid bills and accrued clinical expenses rose 9.8% from the second quarter and 29.5% from year-end 2025. Growing payables alongside the rising research budget means the company owes more to vendors as Phase 3 trial sites open, adding to near-term cash demands over the next two quarters.
🔮 Guidance
Unchanged. Cellectar still expects its $24.6 million in cash to fund budgeted operations into the second quarter of 2027. By our math, that leaves an average cash burn of about $9.8 million per quarter over the next two and a half quarters, slightly above the $9.4 million spent in the third quarter as Phase 3 patient dosing begins.
Unchanged. The drugmaker specified that it remains on track to dose the first patient in the first quarter of 2027, matching its prior target of early 2027. Initial clinical sites are now active for the 200-patient randomized study comparing iopofosine I 131 against standard therapy in post-BTKi WM patients.
Unchanged. Cellectar plans to file its New Drug Application with the US regulator in the first half of 2027, consistent with earlier statements pointing to March, April or mid-2027. The timeline has shifted several times since late 2024 because the regulator required a confirmatory Phase 3 trial to be underway at submission.
Unchanged against last quarter's call, though delayed from the original mid-2026 target set in early 2026. The company now expects to share initial dosimetry and safety data from the triple-negative breast cancer dose-escalation study at a medical meeting in the fourth quarter of 2026, without mentioning efficacy data.
❓ Key Questions
What happened to the European conditional approval filing?
In late 2025, Cellectar planned to submit its European application in the third quarter of 2026. The European regulator was absent from both the second-quarter and third-quarter updates, leaving investors unsure whether the filing was shelved for lack of cash.
How will Cellectar fund operations past the second quarter?
Cash runs out in the second quarter of 2027, right around the planned US filing and before filing acceptance can trigger the second warrant tranche. If the first warrant tranche cannot be forced, the company needs a bridge funding plan.
How many Phase 3 sites are open right now?
Management previously noted it needs 10 to 20 open sites and several patients enrolled to submit its application for accelerated approval. The release confirmed initial site activations but gave no exact count to gauge whether a first-half 2027 filing is achievable.
When will Cellectar report tumor shrinkage for CLR 125?
Earlier filings promised dosimetry, safety and efficacy data for the breast cancer drug in mid-2026, but the fourth-quarter 2026 presentation covers only dosimetry and safety. Investors need to know how many dose cohorts have enrolled and when efficacy data will arrive.